These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 32733012)
21. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873 [TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664 [TBL] [Abstract][Full Text] [Related]
23. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia. Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803 [TBL] [Abstract][Full Text] [Related]
31. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions. Upadhyay VA; Brunner AM; Fathi AT Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358 [TBL] [Abstract][Full Text] [Related]
32. Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia. Gupta C; Kaulfuss S; Görlich K; Othman B; Chaturvedi A; Heuser M Ann Hematol; 2020 Jun; 99(6):1415-1417. PubMed ID: 32296913 [No Abstract] [Full Text] [Related]
33. Non-Invasive Measurement of Drug and 2-HG Signals Using Wenger KJ; Richter C; Burger MC; Urban H; Kaulfuss S; Harter PN; Sreeramulu S; Schwalbe H; Steinbach JP; Hattingen E; Bähr O; Pilatus U Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138036 [TBL] [Abstract][Full Text] [Related]
34. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Kats LM; Vervoort SJ; Cole R; Rogers AJ; Gregory GP; Vidacs E; Li J; Nagaraja R; Yen KE; Johnstone RW Leukemia; 2017 Jun; 31(6):1466-1470. PubMed ID: 28280273 [No Abstract] [Full Text] [Related]
35. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776 [TBL] [Abstract][Full Text] [Related]
36. Updates on DNA methylation modifiers in acute myeloid leukemia. Contieri B; Duarte BKL; Lazarini M Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842 [TBL] [Abstract][Full Text] [Related]
37. How I treat acute myeloid leukemia in the era of new drugs. DiNardo CD; Wei AH Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470 [TBL] [Abstract][Full Text] [Related]
38. Reasons for optimism in the therapy of acute leukemia. Rowe JM Best Pract Res Clin Haematol; 2015; 28(2-3):69-72. PubMed ID: 26590761 [TBL] [Abstract][Full Text] [Related]
39. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions. DiNardo C; Lachowiez C Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639 [TBL] [Abstract][Full Text] [Related]
40. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Kantarjian HM; Jabbour EJ; Garcia-Manero G; Kadia TM; DiNardo CD; Daver NG; Borthakur G; Jain N; Waukau JB; Kwari MI; Ravandi F; Anderson BD; Iizuka K; Jin C; Zhang C; Plunkett WK Cancer; 2019 May; 125(10):1665-1673. PubMed ID: 30668890 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]